Explore 3 Stock Ideas & Industry Insights Download Free Report

News

PG Austin Investors RC Targets $80.3M Class R Offering

PG Austin Investors RC, LLC expects to raise up to $80,300,000 ($80.3 million) through an offering of Class R Interests. The fundraising terms give the manager discretion to expand the offering, setting a potential maximum of $104,000,000 ($104 million).

Nitish Kishor | 08 September 2026

Why Is This NASDAQ Biotech Stock Sinking 29% Pre-Market Today?

Shares of this NASDAQ-listed clinical-stage biotechnology company are down 28.75% in pre-market trading to $17.30, sinking nearly 30% despite the company's own news today being unrelated to any trial failure. The steep drop far outpaces broader healthcare sector weakness, suggesting investors are reacting to …

Nitish Kishor | 08 September 2026

Ionis Pharmaceuticals (NASDAQ:IONS) Stock Falls 10% Pre-Market on Partner's Trial Failure

Ionis Pharmaceuticals (NASDAQ:IONS) shares are down 9.50% in pre-market trading to $52.36, after Novartis (NYSE:NVS), its partner on pelacarsen, an Ionis-developed cardiovascular drug, reported that the Phase 3 Lp(a)HORIZON outcomes trial failed to meet its primary endpoint of reducing cardiovascular events. The disappointing readout, …

Nitish Kishor | 08 September 2026

Why Is This NASDAQ Biotech Stock Sliding 9% Pre-Market Today?

Shares of this NASDAQ-listed late-stage biopharmaceutical company are down 8.82% in pre-market trading to $23.16, falling alongside broader weakness across the biotech and lipid-lowering space after a competitor's cardiovascular trial disappointment. The decline reflects sector-wide investor concern about the cholesterol and cardiovascular lipid-lowering drug …

Nitish Kishor | 08 September 2026

Novartis (NYSE:NVS) Stock Plunges 13% Pre-Market After Third Trial Failure in a Week

Novartis (NYSE:NVS) shares are down 12.87% in pre-market trading to $139.40, after the company disclosed that its Phase 3 HARBOR trial testing del-desiran in patients with myotonic dystrophy type 1 failed to meet its primary endpoint of improved hand-opening speed versus placebo. This marks …

Nitish Kishor | 08 September 2026

Pharvaris (NASDAQ:PHVS) Stock Soars 20% Pre-Market on Positive Phase 3 HAE Data

Pharvaris (NASDAQ:PHVS) shares are up 19.66% in pre-market trading to $42.18, after the company announced statistically significant, positive topline results from its pivotal Phase 3 CHAPTER-3 trial evaluating deucrictibant extended-release tablets for prevention of hereditary angioedema attacks. The stock had closed down 1.15% at …

Nitish Kishor | 08 September 2026

Roivant Sciences (NASDAQ:ROIV) Stock Soars 20% Pre-Market on Positive Phase 2 Lung Disease Data

Roivant Sciences (NASDAQ:ROIV) shares are up 19.81% in pre-market trading to $41.85, after its PulmovantSubsidiaryannounced positive Phase 2 PHocus results for mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, a condition with limited treatmentOptionsand high unmet need. The stock had closed …

Nitish Kishor | 08 September 2026

Royalty Pharma (NASDAQ:RPRX) Stock Falls 8% Pre-Market on Novartis Trial Setbacks

Royalty Pharma (NASDAQ:RPRX) shares are down 7.66% in pre-market trading to $59.06, pulling back sharply from Monday's 52-week high near $64.38, in an apparent contagion move tied to Novartis's (NYSE:NVS) late-stage trial failures. Novartis shares fell sharply after both its del-desiran, for myotonic dystrophy, …

Nitish Kishor | 08 September 2026

Why Is This NASDAQ Gene Therapy Stock Down 13% Pre-Market Today?

Shares of this NASDAQ-listed commercial-stage biotechnology company are down 12.76% in pre-market trading to $19.63, falling sharply despite the company's own news today being entirely unrelated to clinical trial data. The decline reflects broad contagion across neuromuscular disease and gene therapy stocks after a …

Nitish Kishor | 08 September 2026

Why Is AstraZeneca (NYSE:AZN) Stock Trading Modestly Higher Pre-Market Today?

AstraZeneca (NYSE:AZN) shares are up 0.31% in pre-market trading to $163.21, as investors weigh a busy stretch of pipeline and regulatory news against mixed analyst signals and broader healthcare sector weakness. The stock closed down 1.26% at $162.70 the prior session, and today's modest …

Nitish Kishor | 08 September 2026
Support

Hi! How can we help you today?

Loading…